ADMA Biologics (ADMA) 9 Aug 232023 Q2 Earnings call transcript

Good afternoon, and welcome to the ADMA Biologics Second Quarter 2023 Financial Results and Corporate Update Conference Call on Wednesday, August 9, 2023. [Operator Instructions]. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce Skyler Bloom, Senior Director, Business Development and Corporate Strategy at ADMA Biologics. Please go ahead.

you financial us quarter results recent updates. thank discuss afternoon XXXX and corporate Biologics' ADMA for everyone, for this joining to and Welcome, the second Executive by Chief President, Officer and Adma President I Executive of Financial Adam Manager joined Brian Lenz, today and am Chief Biocenters. Officer; General and Vice Grossman,

on overview call, then results. Brian and Adam introductory of During XXXX progress, company's provide today's quarter comments and provide an corporate some will provide the second an update will financial

brief some call provide remarks before then the will Adam summary opening up for Finally, questions.

financial detailing www.admabiologics.com. Earlier at and today, press recent is a achievements we release corporate website our certain issued the available release second updates. on This quarter XXXX summarize in results

making intentions, provisions forward-looking the Private for during that Reform begin represent or forward-looking which the call expectations safe assertions formal harbor under Before remind we you be our today's company's concerning I'll purposes of statements constitute Act the comments, future beliefs the of events, XXXX. Litigation that will Securities we

All as differ forward-looking today's expressed this actual which to subject announcing cause uncertainties the and from such our release press detailed risks call as may factors, those or as with such implied the in in results filings SEC, statements results by statements. materially well to are

In date our representing views only views of forward-looking not addition, the relied any subsequent upon as as statements as this date. should of represent our any be call and of

on today the such notice in issued obligation section any laws. by to statements, any earnings refer federal report important We these annual as XX-Q our December update as our that XXXX well from on the Factors Risk of could ended discussion actual XXXX, release for section forward-looking year We disclosure as XX, Form quarter differ factors disclaim to statements. XX-K to materially our the XX, ended June report Form cause of except results securities specifically the the in for a you for XXXX, we quarterly required

that adjusted note comparable the is turn our call call earnings discussion Grossman. Adam? like in I to these includes now over EBITDA financial GAAP today's loss. and certain reconciliation net measures on of to With non-GAAP said, adjusted would the that nearest available financial Please A the to metric measures, Adam including release. non-GAAP

Thank first We're the you, during second to we proud grow adjusted growth that million, sequential quarter to EBITDA $X.X XXXX. representing Skyler. totaled rapidly of which to report the XXX% quarter compared our base, continue

This million impressive was facilitated second the year-over-year disciplined gross operating increase quarter. growth growth underpinned and has XX% resulted meaningful by in in Which in This robust profit by continued management expenditures. reached of accomplishment an revenue leverage, $XX.X total revenues. operating

raising upwardly strong the the established provided. we year from more XXXX than total to revised are fiscal guidance momentum previously revenue $XXX on year-to-date, million, million $XXX Based now

confident remain our we trajectory XXXX in of Additionally, in EBITDA and beyond. growth adjusted sustaining remainder throughout the

in meeting business million trends and at all increase otherwise million, reiterate have fiscal or and XXXX enabled encouraging targets. to exceeding fiscal $XXX respectively, ADMA confidence The and XXXX least guidance indicators year year total revenue $XXX compelling and forward-looking profitability to

populations. targeted the continued efforts most unique combined comparable with medical ADMA's attributable billion XX growing We is in We success company deficient amongst market biopharma education our stand-alone adjusted underserved core business immunoglobulin model, unique USD biopharma this EBITDA revenue few ADMAs growth financial product guidance, the peer believe focus portfolio, and an our end innovative our immune importantly, and elite on among year-to-date scarcity generation. with to group. a treating patient asset profile, results, value, select ADMA our financial view, In place financial companies with coupled the profiles only increased believe position

is deficient United has provider this patient unwavering in commercially, to immune maintain the believe it immune on the been marketplace. of has And primary concentration in specialized the enabled its as Since position States that globulin fastest-growing focus ADMA its ADMA we launching population.

we paving prospects During expected this quarter, promising a number way the new and patients share, the market in second and record for go-forward immune-deficient success treated business market strong gained of segment. primary

mix product ASCENIV in evolving driven utilization therapies. continues maintain its unique Our its strengthening by to the believe and among growth immunoglobulin favorable We XXXX. and of trajectory is composition

landscape during evidence value patients compromised at-risk or the proposition to Society The And of immune Immunology immune its articulated real-world ASCENIV our PI. quarter. XXXX the Clinical presence during second Annual primary which at took improve globulin immunodeficiency, place for was with further within the outcomes Meeting,

ADMA presented continue spoke who in meeting, to challenges nationally noted therapies, recognized recurrent complications. associated than with RVis viral sponsored or associated patients with experience of infections real-world of and symposium patients key At the Despite medical a respiratory by immunoglobulin about standard experts PI the leader, a availability PI. education XX% more that well-attended this opinion infections with

along certain than bronchiectasis, data Of experience decline a causing that meeting X/X exhibit patients for bacterial risk lung and issues prolonged continue this of poor adversely particular their CIS outcomes Clinical to of at in present life and T patients population more can cell outcomes. presented highlighted RVis PI for impacting experience defects, with quality with significance, function, rapid families. and superinfections that the thus and

with at-risk presented real-world that The an report was ASCENIV. patient treated successfully case

persistence real-world expansion ASCENIV product and are existing encouraged prescriber velocity in reorder the We of of among a accounts signs lines, prescribing and seeing record profile patient clinical practice, continues see Along these resonate bolstered are settings. by customers. to new of unique to we

product beyond. over share of We anticipate overall periods continue to therapy that will and even this mix the coming an capture portfolio greater our

market growth further increase enhance that quarter recent advancing position and our in made potential progress periods, we will, in the earnings the opportunities if second power. our in successful, During

at rapid to This XXXX advancement We and beginning product's growth is opportunity expected manufacturing the forecasted our such into is of and anticipate beyond. later batches profile production plant these multiple be in the expanded XXXX One increased may the throughput X,XXX-liter production capacity, trajectory. realized through supporting scale. and recent expansion improve successful margin ASCENIV benefits

and Secondly, initiatives successful transformative analysis upon of laboratory the showing for impact is commercial yield requisite of to production advancement the both development potential our to if potential has revenues financial with with provide The The margin initiatives, upside potentially receipt of company peak scale made regulatory enhancement and promise. increase successful, approvals. could yield of the the validation and scale enhancement company's progress targets. peak

product progressing immune post-marketing may our to studies opportunities, are label provide our and Finally, ongoing our globulin compared strengthening peers. further clinical expansion portfolio well

growth As materialize. have yet from not provided we should in like guidance I'd we detailed increased include release, initiatives revenue they press have does potential today's upside these the reiterate that to any

to developments. the these on updating forward look market We

On financial immunoglobulin supply portfolio's us are the to of revenue front, support The end well and contracts all we collection for immune our RSV to normal Biocenters supply our meet source network revised the secured expansion market addition rapid provide chain forecast portfolio. plasma needed in flexibility, demand. third-party with and to believe growing contractually upwardly we globulin supply our prepared our

Currently, tenth have we centers are we established anticipate X operational, in cost-competitive supply network our self-sufficiency. our before after believe FDA FDA center, XXXX collection all with for which we achieving year-end licensure collection will XX now complete plasma licensed. And

our journey ADMA's with the is becomes our and on employees. evident the result of direct success achieved, a exceptional exhibited and that dedication It reflect hard we milestones is unwavering by the member each As to we've it and complete recognize us passion appreciation that our table, vision. organization's that the operations brings to control commitment, enabling with our driving we and take core of team great triumphs diligence work aligning

ADMA in expected the foundation solid put day for paves this the success out. teams, BioCenters relentless to gratitude in our greater Biologics your day way believe and efforts the in ADMA even and for We extend We future. you entire

this the meaningful of us. make those spirit Your It who but a make rely XXXX the the our remarkable review and in call workplace to to teamwork exceptional. contributions turn fuel accomplishments, lives the truly difference I'd Brian of second financials. said, not only like is over our now for that quarter collective also a With on

press second earlier later discussion we which quarter Adam. XXXX also will with encourage our today would our make call. conjunction afternoon, you in XX-Q and be during points comments we second this release to a issuing We Thank read will our financial you today's quarter results, issued we outlining and

of discuss key the now highlights from some the second quarter. will I

approximately June the X during and patient mentioned XX%. The increased for our utilization is This or revenues as X Adam and Total approximately million the XXXX. million ended our expansion sales of represents XX, well earlier, acceptance were $XX.X base. XXXX, of $XX.X immunoglobulin payer $XX.X higher ended June as to XX, driven our months products of As months compared customer physician, increase by to as increase attributed an million

the our from the long-term offset partially million consistent product during expectations this plasma with the of first $X.X agreement revenues sales of and BioCenters supply third-party during was The decrease fulfilling growth context business our in our in quarter by was in XXXX. a segment, quarter plasma

Our ended million profit represents this X million increase for period $X.X to XXXX, the gross was million. the $X.X $XX.X ago, for and XX, compared a June of an as year months same of

XXXX. increase, margin the to quarter of of XX.X% XXXX compared of result As in in as achieved of XX.X% ADMA a this a second the quarter gross second

resumed margin gross normalized have accounting course grow took and units, well our XX% to operations would coming an rapidly an a of to cost million on responsive quarter to We continue company to disruption, to for sold a estimates which steps profits normal XXXX paved been across the second contemplated over and the basis. periods. Importantly, quarter ADMA XX% believe goods $X.X the estimated pertaining have pathway is on IT business second impact remediate production gross

compared revenues, expense. narrowed million the second net and consolidated million, for interest of $X.X $X.X decrease $X.X attributable The Our XXXX in $XX.X was million million of for increased offset the the operating million due million increase the mainly of in partially $X.X second to XXXX. as of net income quarter the was $X.X profit loss gross of quarter the interest loss loss increase to to by

to ago. nonrecurring for improvement. $X.X months total of significant the to EBITDA an net the XXXX, Adjusting related grew same ended of was June disruption, X adjusted the loss $X.X million adjusted for million ADMA $X.X second EBITDA compared million of adjusted year period-over-period loss IP million quarter XXXX, to the of our $X.X as in a charges a period XX, for

gross of primarily and million growth receivable. XXXX, primarily EBITDA had The $XXX.X cash sales profit. driven million this accounts of $XX.X cash balance ADMA's We capital increased At by $XX.X and June adjusted ADMA improvement $XXX.X million inventory, beyond. equivalents million, remains throughout strong. adjusted and of continued EBITDA year working of consisting sheet anticipate and XX, was of

million. liabilities was This by current offset of partially $XX

in And ADMA and pending we final XXXX. X which FDA XX BioCenters with material now from the collection centers supply anticipated forecast period, operational of self-sufficiency our licensed X same is center plasma centers. FDA raw plasma network for Lastly, all licensure consists of collecting year-end our

collection we remain the that, record for in achieve to continued the closing encouraged highs, over I'll real-time above levels. considerably remarks. by We back remain our Adam traffic improvements organization's volumes, With call turn foot and prepandemic now all-time which to and donor

company's the an The best-in-class targets. at our With we in and ultimate Brian. stronger revenue bound solid our a you, or foundation than supply anticipate confidently IG and to visibility newly us meet peers. ever, business Thank forward-looking and trends we amongst profile maintaining our financial growth exceed commercial believe margin infrastructure, our achieving allows potentially chain growth upper and are increased

income immediate to profitability. ahead, we net towards period EBITDA grow and expect the In adjusted advance

new the our profitability growth We near hold pursuing are about further longer and enhancing for we term. the additionally to committed they over and are opportunities, potential thoughtfully optimistic

to are further and XXXX quarter excited on of and We second momentum value. to drive stockholder success the the of build

donate agreement company. forward the look support advisory Morgan ongoing strategic of would your in evaluation like open like plasma for and The ahead. our lives to to make now and that journey stockholders, priority efficacious to our the lives. our in with family trust safe financial and your company. a help its Thank up investment for terminated questions. to continued Operator? ADMA and your remains you, our I and your for business and you Stanley. support products that, I'd neighbors. help ADMA thank as for With quality, corporate save mission alternatives Although friends, save high top helps continued call Please We advance to

Instructions]. [Operator

with comes from Nachman Our James. first Raymond question Gary

guidance.No, quarter nice raised afternoon, it's Good to here. good be and

put status the more about reimbursement you you're what what's with talk are So given Adam, higher seeing for getting of could the -- Specifically, the maybe and product? ASCENIV, types it uptake price patients on point the

is -- you so the are ASCENIV that And your currently the uptake persistence the then then the what ASCENIV some seeing with that to both expand what mentioned of even initiatives also further? patients of revenue you're portion And versus for and physicians BIVIGAM?

There's great lot the there. questions. for a you Thank

prepared on touch roughly of your our of can I seeing I investors revenue emphasize quarter-over-quarter. in We're hope the We're from think increased the question getting third remarks we've from analysts, one from who your answer question a because first, sequential are growth been coming I to We in tried -- So say press lot What everything. patients. to is higher-margin seeing release X/X these products. I the this about uptake.

And patients. are or immune diagnosed trying These these we're forms to with that very are more hard immune-deficient really X are that delineate deficiency. people of primary

of T viral co-morbidities. issues. other immune these They patients Some patients cell have factors. increased respiratory They They risk And medically may have even bronchiectasis. compromised. infections. They be have have have risk an

immunoglobulin that of They to to should seem therapy, They miss brand there no The school. don't to and It was say, to work alternative continue These is IVIg, prior standard I from are X but that since short standard well. have typically who switching just patients. for problems. on do ASCENIV, long story these days patients ASCENIV, another. to are continue was

made offers type So of really product protected that's by in patents. first a unique way where our it's ASCENIV the

at our that out now public plasma improved differentiated data blend in high to use the more outcomes in I Patients on effort these it's seeing been tell point multiple this seeing time. that a antibody are really, They're We're product Gary, shows donors the commercial And a We in is domain launch are since have respiratory we certain years And collected profile. then a that tested staying pathogens can uptake. product. therapy durable. what patients. viral this we grassroots making a from has year for plasma you, is in are and rapid to third that we're here. the of What that's the there tires

that in reimbursement You types. asked organ not have and more pneumonia. or We're patients documented payers about list the they a per Again, have seeing system of money cost Patients they're one these bronchiectasis. persistent on patient and there. challenges transplant the times of because after infections, patients right multiple year. Many that lot hospitalized, chronic go

the for results patients. J-code, So existing that in product. immune momentum try we I is the reimbursement clinicians has there. because a can unique out rationale once they is being And received their you penetrating in pharmacoeconomic accounts, gaining every the deficient problematic the additional IVIG are tell to see are patients, more willing product

And we're this innings. a in still the early rapid seeing think more and quarter-over-quarter. uptake We is ASCENIV utilization rapid that

market, to target primary with As feel XXX,XXX immune somewhere or at diagnosed and XXX,XXX the deficiency patients, we look these immune-deficient of of X XX% there's between people roughly to more XX% forms our be roughly primary could we market.

So tens patients. of thousands there's of

potentially we scale. the at feel liter haven't making even that we surface. the So ASCENIV We're X,XXX now scratched

for seeing made that we last year. product you're today that margins the the product So is

are that is was the from that seeing you're expenses revenue but our generating year. we made today, product last So

gaining can more And as than more spending you yields, we're tell at looking employees have, the we're we're pat job don't gaining yield, less better. just they efficiency, and They're what we're better is as our a more I our costs as that I operating our getting and business on controlling efficiently back. doing ever better is

our that So the is we've backs. got what we We intended. confident we doing drug at think wind feel really

a the market focused And on company on was founded. bit, maybe primary we've immune-deficient touch I'll since too, that little just this the been

in the about patients ago. an just up medical and that the where where just the since Jerry to start our are starting making talking the founded of money That's immune patient is many talk deficient immune now industry we primary This need immune the and been competitors years because today our larger unmet deficient -- up We've company why I recognize is inception. for isn't only motto Our status population something I why XX immune is, we're to about put this of compromised. it's company advanced therapies deficiency. as

benefits the really for conference that vocal deficient is the today. benefits that that doesn't vocal the I've champion, that seeing this we're on And And these champion a said been we've We something multiple and immune of problematic patients we're We're feel the proud and we're the population typically that the very voice. of have doing seeing in the work are calls. market.

most gave So I that question. you Hopefully, answer. it a touched a you your was asked. on I lot of long

a Just follow-up. quick

X/X terms 'XX in when So year BIVIGAM you guidance? the and ASCENIV upside are further it consider factoring ASCENIV mix shift some context yield around from 'XX, put Is and for for just what and opportunities enhancement. then also to a guidance you mix and in the of potential and then the of raised expansion that this then in And the X/X. and magnitude label greater

in if limited you your plasma are those So you some achieve targets? way of other can any supply, with

our smaller XX-XX of Gary. we upon we're questions is driver Nabi I split the ASCENIV share. and being closer said what revenue and BIVIGAM that primary higher-margin products, Great the ASCENIV. utilization and is to what have Historically, We're between depending -- said And in the we've that split always seeing and seeing the Brian ASCENIV being increased also, Nabi-HB. historically a last And that quarter. couple move calls of said XX-XX

on growing We're all sides.

plasma tell fixed. years, split XX-XX, starting not about Roughly that's profile to like XX% I ASCENIV is looking donors that antibody used you the what is out potential. plasma of the maybe the here have get certainly batches. in material a there even the to So for, for a XX-XX a can is that as But it's for potential there we're

run that donors we you the it's profile collection plasma. plasma which for not got collections. that power ASCENIV, bonuses them that overall what we plasma run is may of the is tell more people that XX for to plasma the say we're I in that choose more. than and And of for to collecting. we special just may day. being antibody the I our the What pay promotions we're it's XX% centers open we've We've got And where XX% that But have can and control collecting collecting that ASCENIV, can donate come

will well of bringing which That labs we're the in-house, to around strategies identifying about do our implementing but cost as costs, reducing going these calls of accelerating as for We're not I've on paying testing. donors lower which in-house, turnaround talked increase some testing time margins. previous testing, this and goods to accelerate our ultimately third-party is

margin we've XX% think said we plus. always that ASCENIV roughly future, as -- be into could the an XX% product. So is We it move

enhancement strategies. touches portfolio. our yield on touched You manufacturing Again, entire that

think to products, this more could I potentially in that say much of how prepared All not our we're yield anticipate. prepared be we transformative. we pinpoint remarks, But my did

So that yields. mix been to the greater the raise than that that today really we've about. not and The talking XX-XX does upside. It anything not given I've financial guidance increased does contemplate contemplate

you're So know for while. getting we're dealing the a but other know been the us, Gary, just call I to me concerned. very with have on analysts

for have investors while. Our with been a dealing me

beat We like expectations, in set We are and to intentionally our to conservative good like guidance. them. we

is for upside So substantial I that do here. think potential there

end made profitability in are But got data to think substantial taken. guidance. in here batches of fast day, order that conformance that we things we've yet some get our nothing the -- in of and time. and take and at stability do not the world work And contemplated biologics. metrics the upside got moves to We've

with next Anthony comes Petrone Our Mizuho. question from

of history another the really X on here [indiscernible] now, here just quarter, I think of and raise. Congrats kind looking quarters at great

were practice, an One interesting the they call to benefits to that, seeing points ago call. we in case team. exploring great hosted and actually come Maybe, just that data where "refractory it's So in few a congratulations out they weeks immunoglobulin. few are and patients the these in particular, use ASCENIV, to for see immunologist this Adam, traditional" a individual's of is

treating immune patients. complex not respiratory you responding broader anecdotally, susceptible that What think infections. So immunologists you They're about patients, company They're follow these on the from that maybe your complex. to deficient hearing are are standpoint are a and these when from to set immunoglobulins. of

first So that the be question. would

benefits call And more the points perhaps order around is of of to this X the second in of data complex question really product ASCENIV be there came out reach that these that unlock physician is to needs having of more education the patients.

sort so have is go-to what sales follow-up here go-to-market a of solution patients? for strategy of Are the is efforts here? a the And of And to these Brian. sort now more becoming reach increasing ASCENIV I you that

that you at Great And give I I think of grassroots story metrics are durability you I see answer for again, X that patients easiest you increased the out on well ASCENIV. are Thanks, question. since that that's building on appreciate your the support. financial the Anthony. been the revenues, is the can see continued doing very The business. time, drug, beginning. the I mean effort, a the way patient playing the

have a doing patients, for when happen that's doesn't outcomes don't improving you you what and promise, stop. product that these That full isn't

collect that that changing? part parlaying company. call have close and we've lives. the on your We've e-mails. And plasma. that's some next, mean others the conversation the affected the the of even yes, the are all of seen to this We what's into payers. be We've think seen to but ADMA it costs the e-mails it the what's costs staff, I seen I candid, from question, prescribers, more second the e-mails the To drug to the from where more, with patients.

that And what the are It's way. that hard product measles,polio antibody find an patient diptheria. the to are try that perspective from CFR in outcomes, doing you with is them, patients what But can as you IG product And to has variable outside FDA reproducible for better. other immunoglobulins is -- I see profile find antibodies a and very when these tell of around the reliable, a we not them. keep and it's to these in And we make that we donors. consistent

year, and this communications to our you've Something where to done the for beginning and affairs, you'll We've hand see patients group. end I see want talk medical who next ambassadors by in think more that the they something so moving of of scientific journey. now about I that maybe patients towards, be the that maybe "Hey, is And marketing, year got say, my drug. we're think in companies like that story. tell I'd mature their I'd have like these you well drug raise to got my

the is And something information we're the about about, number to seeing providing spending from patients as which education that I think medical think to market them I physician of a efforts not this asked of and that you we out it's advocacy dealing only patients are immuno out in with the And more there. and our patients furthering alternatives resources more the also community, talking but with primary with today. availability that patient are themselves, deficiency groups, to there time progress

that you're see. things to these are think going I So

don't of it, spend We need not looking we're to. spending XX We're force, and not we've put roughly we our are commercial said in small We've need people pushing we've I We across got XX, couple Anthony. exponentially. real XX the our mean, where team. in hell meaningful name got It's want the lights probably commercial we jobs, of a to a not -- here. reps outcome. growing always that that money total, and has country we're just open for

Clinical education regional Society the rolling symposia, think doing scientific at meeting, medical Immunology highlighted and out we're the the And as doing we with efforts speakers these we're I as programs, that speakers bureau. a with we're

scientific really seen the our that the medical physician think of working extremely and proud But the physician advocates. group marketing around I've to that patient is I from most education and I'm affairs work well. communications

and once will let able certainly will they they're go of IG journeys regular people becomes a do stories then the of And work analysts the start of public hear our all on IG, the back ASCENIV in to And because available, this school. is meet and a to real-world suffer on folks be and and domain. we'll for denied they they and don't all sudden, years, didn't treatment stuff are they And IG criteria that the are people on be couple of in who know, who that well. then but

been the it's and patient, Gary's the starting of And coupling we're these the caregivers comments founding to fruitful off, more patients. ADMA a on pay It's struggle we're and the a got just really again, I matters. not thousands benefits every to all that's seeing to much making difference made mean that of I it's we're see question. families, of benefits many and tell the that the patient's because work going of of ADMA, coming you, lot to this day. the And really Biologics it's in lives I through so

And patient something we It's really of BIVIGAM ASCENIV making the not is profile safety provide too presses. BIVIGAM to on proud to that here. the think population. product stellar. -- we that U.S. drugs we the profile, we're using deficient centrifugation, are the only filter company I'm We're aware and in Both products of immune

just quick very That's follow-ups. helpful. X And

queue. So pipeline. just back I'll in be would on hop One

heard at we the FDA haven't of subcutaneous curious, Brian, just anything and of Is ASCENIV. at cards clearance. BIVIGAM X point? kind XX that have plasma on in then total, And versions Just centers on supply, some in we're

to kind the the right collection you where when we're the next X today. XX, years, network base out plasma X look over do number? XX% grows beyond think you at Is the Or of that

Anthony. Thanks,

armamentarium. to look, penetration yields, let right, ways and finding the the when in But saying, off our is IP So brand we we've more value maximizing you market building time by got penetration, start I'll we'll know. expense. little right certainly awareness for laser-focused And just of on now, ASCENIV, we're unlock

on immune deficient penetrate is we to at markets and X,XXX ever can continuing have I here. We're product immune is focused making focus the scale. -- here into the that It's more grow just primary what liter we're what deficient you driving the the tell know secondary working. that's already That's the than we working. and what

we to down, made and at in-house. first production more so and making a this time. going bringing looking through far. the fill be strategies yield year. drug, we're all output made But and more X,XXX plan, working was all more batches year year more budgets it's having then the plant, the next enhancement getting for We're couple plasma that couple unabsorbed This with of batches finish that the on we've you

being going Anthony. in you ADMA are otherwise, we're over I mean to in talked or a we our more. never and and you million early never and in years these at And letter, able are I'm have million days tell ways have here be the beyond ever they I I'd had took over a anything guidance or warning thought to margin we I'll I quarters. this profile about that excited, years still that that here. XXX raise improve now would I to plan $XX very million drinks When that we the thought

than million This plant under in we're a generated $XX more we're prior beginning. management and the that never and quarter, a just year, in doing

seeing But it's the start happen. I question to soon. on and and going as likes So Brian told efficiently Mr. up the to next we're let very doing to say better, it say cash it's I'll keep call, think it ADMA you're the centers. to days, do you I to staff to the more that's was is what going the us. early do what's on make flow What's the next call, I answer very, you to doing, for this Wonderful it on

Adam. you, Thank Sure.

also cost trends, better of So we're centers, higher per than collections. areas, day on expected. weekly say, seeing question we're in encouraged and as momentum I are centers the much We're record mentioned, plasma our number some fees, by your donor the -- very We're liter seeing seeing efficiencies regarding lower daily Anthony, positive I'd performing collections.

focused looking center -- not on all We're XX really built, any We efficiencies. labor more and are are don't centers we're XX building than All XX centers collecting. centers. at

July, getting by certainly approval supply it's of ninth self-sufficiency. saw you our plasma received tenth us, FDA for As all our center in encouraged year-end. about And approved we feel center we for

leaders CapEx of coming start pleased center for And that centers will we goals we're those right the no to we're forward look set our we're a collecting of revenue in fully are how now again, the we again, us. And putting And fruition for and the the with as build-outs. And the through centers, plant. to place that number very XXXX, ourselves be certainly for revised numbers is further further the performing. self-sufficient no plasma in for guidance beginning

Our next Kluska Cantor question from comes Kristen Fitzgerald. with

really here. another quarter on solid Congratulations

I have tight lot didn't KOL story treating the and question about expected. the community in a than First appreciate it fully is physicians that more something maybe really are is I I

continued data findings of your case I you've word positive of of mouth that showcase added trading aware how the benefits to is just around here? the estimate just studies. showing and to community So you that the is and given much these ask ASCENIV wanted

as representatives these next out years the you looking the in beyond And terms word talked patient of you're then in and conference potential anything into or that X appearances so, your on working more terms well. getting about guidance like of

you think have Sure. And were... -- at I Thank Kristen, you you, were CIS, very at much. if I been may

was I Yes.

look, think -- see learning large just taking the for an certainly that more there's control about. KOLs, more think of population. interest there is are we a handful prescribers clinicians there you are But But if you there's that that PI thanks there, a of headroom. out We that it, many So will, part many there.

our Immunology market of publications up Clinical the and paper. immunologists a to research and of pick was journal about right? ad world couple to experience like the Something tells which and as they what that like thinking and you print the campaigns, other digital. -- started of This were actually I talking, flip us also is print is we've actual strange, -- just My running is that

So that, started print ads. running think And speaks to recognized. be that fact I is that we to the starting ASCENIV

a name deficiencies. with immune is It's synonymous brand that

available I for in the think of hard a name opportunities us joining that very ASCENIV with is name worked population. there headroom really that do among base. gaining penetration there -- prescriber the lot ton a think more we've the immune-deficient is existing I at it's of we something ADMA, that feel But confident

institutions. XX%, impact more the more think as we XX%, patient that pharmacoeconomic is publishing domain, about same-store And these at the public data, roughly we benefits, has as population of data to more even existing as get Remember, going growth we're we're see XX% prescriber's every starting in show co-morbidities. to

are tapped that subcutaneous. tremendous about asked We yet second. infusion I there specialty there. that question, And new that on really with companies, just and touch pharmacies a for into. prospects I growth was your haven't new prescribers think new upside And we see do think but I'll don't it

today for they who intention no and a I that. their publication was on own, in there say one, but go another that immunologist, did that the administered we from get was route. don't subcu that, of subcutaneous to While which a route a on can want I have to a believe recall European I to administration. ASCENIV study back meeting, you publication I KOL, at

think get prescribers I that with and about it the are comfortable what is drug, and use of question But more ways. in starting answers your I is learning can the that, that to part say novel that they're product

a for lot to we answers feel question. there's good of that that Hopefully, So room grow. the us

then a providers perhaps questions, on consistent provider more And pretty how more side. those basis? Yes, you're on in it you then having too comment thanks. challenges, terms ASCENIV work trends And ask of provider not you it little is noted a that that do the level can I'm curious with hesitant but you're the -- bit does really the with if on you many you

there. got to authorization I We've out or so prior market mean anyway, great team. I the getting evidence We data access want the to data, of say it program. all I times. a patient I say many mean based. I a many whether label IG on said XX%, a requires IVIGs, is assistance it's got want XX% great

unheard So product. the whole a the the to of from require for it's for prescriber and payers the not bunch information treater of

the the the in risk the and seeing in type. patient payer population right product we're patient right right of acceptance factors, co-morbidities with Again,

that to they're going need but not is and product, is public ask a split, the patient the product for value about If XX-XX a doesn't you private proposition for resonating. between get it. the mix The

IVIGs, different say, hospitalized. said -- has you've heard their patient bacterial -- products, Our They failed And being we've a is therapy. been X, quite used They after they're preferred tell in X, X you And IVIGs. best treatment I'll keep it's X end has me you the ASCENIV suffering. they patient's tried if the frontline actually. different coverage will. getting a X, pneumonia, the is the all try day, payer later encouraging And never of journey, never at ASCENIV.

because that improve people not your nowhere going your that you that's like ASCENIV life. think save we're what after that's going to is to I'm And that for. say And us, what to and else, some turn, and to not it's going resonate, them, analysts, compute the failed else have doesn't to everything product that We're you come seeing. we're are I investors, life. that's doesn't fine. to

But BIVIGAM much product for you. as in when for that ADMA. at not happy profile you on margin the we're [indiscernible], inventory. drug. any ASCENIV the produce right of be get can Come We're to at We've batches ASCENIV, day. need when the everybody is care frontline plenty trade and to can the patients therapy. here got has now, seems I We to And look of to don't market as

happy for It's immune And it we're meeting we're all something does to out the it lip this if collecting time, are say the to of committed communities, that patients it the our not years. the very plasma been And to service. lives pleased can benefit I've and I help. more deficient matter? for patients . advocacy why the us. team It the there saying and is these matters patient because underserved patients, on counting and product

company we down you We're -- And which at the peg my the our the first because here ago, keep X of move of and going said forward. what luck KOLs you're out company the are to We many peg forward, Adam, I me, was many, to when to what that's to moving is ADMA. first do different. something years got do

but a frontline it's So of fail you Kristen payers not couple IG, a after pay. therapy,

you've you reaching IPO-ed XX are you all today. about should know so made years the about you Great. progress And to Okay. I guys feel very proud since

congratulations on So that.

We're corner. the still With still net income here, growing live. around and EBITDA

and will this to turn closing of Ladies Adam it over question-and-answer gentlemen, our call. for portion now I'd remarks. conclude back to additional the like

Thank I we're for Again, you appreciate and attention into in the innings. time. think Thanks I early your still you, everybody. dialing interest, the call.

very continued appreciate and our be of collection appreciate healthy We you. we visit Plasma, you a X a Donate Do I admabiocenters.com. near lot and may save your great help lives think there's support. of here, upside and that evening. centers stay have visit XX

Ladies and disconnect. call appreciate may you conference today. and now the We gentlemen, this does for conclude participation, your